Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Business Wire•24/10/2026•07:00 ET
0
Key Highlights
- ➤Incyte (INCY) and Genmab (GMAB) launch Phase 1/2 mCRC collaboration
- ➤Study evaluates INCB161734 plus petosemtamab and chemotherapy first-line
- ➤Genmab will conduct the study and Incyte will co-fund it
- ➤KRAS G12D mutations occur in approximately 15% of colorectal cancers
Expert Statements
Pablo J. Cagnoni, President, Incyte and Global Head of Research and Development
“Metastatic colorectal cancer remains difficult-to-treat, underscoring the importance of evaluating novel combinations grounded in complementary scientific approaches with the potential to enhance efficacy”
Pablo J. Cagnoni, President, Incyte and Global Head of Research and Development
“Our collaboration with Genmab will explore the potential of combining KRAS G12D inhibition with LGR5-targeted EGFR inhibition and standard-of-care chemotherapy, with the goal of advancing a new first-line treatment approach for patients with metastatic colorectal cancer.”
Judith Klimovsky, Executive Vice President and Chief Development Officer, Genmab
“This collaboration supports our broader development strategy for petosemtamab as we explore its potential across treatment settings and in novel combinations”
Judith Klimovsky, Executive Vice President and Chief Development Officer, Genmab
“Partnering with Incyte enables us to evaluate this investigational combination in patients with KRAS G12D-mutated metastatic colorectal cancer, reflecting our commitment to research collaborations aimed at expanding potential treatment options for more patients.”
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC)
Get started
Create a free account to read the full story.